Yichen Wang, M.D., Ph.D. Email & Phone Number

Stamford, Connecticut, Us

• Primarily support HCRx’s research efforts and participate in HCRx’s business development and transaction-related activities, including financial analysis, transaction structuring and due diligence

Boston, Ma, Us

• Spearheaded indication prioritization of a pre-clinical small molecule asset for a global pharma, conducted TPP development & validation, clinical trial design deep dive, and revenue forecasting via primary & secondary research• Supported opportunity assessment of a neuromuscular rare disease gene therapy asset for a leading biotech, covering key topics, e.g.: treatment & competitive landscape, regulatory & PMA policies, paving the way for clinical trials in 1H2020• Co-led strategy evaluation for a radiation oncology company to identify opportunities in the radiopharmaceutical field, conducted literature review, pipeline analysis & KOL interviews to assess market attractiveness & strategic fit

London, London, Gb

• Provided go-to-market strategy consulting (US & global) and solution implementation for top 20 pharmaceutical companies, worked on various projects across all stages of drug development and different therapeutic areas• Led a team of 4 people, and collaborated with 3 cross-functional teams to launch a first-in-class Oncology product for a top 3 pharmaceutical company, with potential to reach $500M in sales• Executed comprehensive primary & secondary research and developed 15+ assets to support the launch of a new Psychiatry product for a top 5 pharmaceutical company, with predicted peak sales of $1B

• Delivered strategy consulting for pharmaceutical and biotech companies, utilized primary & secondary research findings to conduct opportunity assessment, asset identification & evaluation and growth strategy development• Conducted analysis on 2000+ companies and assets to support M&A assessment for a leading gene therapy company, led IVF asset licensing opportunity evaluation for a multi-million-value public biotech company

• Coordinated collaboration among 4 cross-functional teams, expedited preclinical research to achieve key milestones, moving from cell line study to animal model within 6 months, published a first-author paper• Participated in the establishment and validation of a novel gene-editing technology’s usage in lung cancer treatment, and advanced the pre-clinical stage therapeutic asset into clinical stage

Newark, De, Us

• 5+ years of research experience, participated in $1M NIH grant research, with 10 publications in renowned medical and scientific journals, established the 1st murine surgical model to study a rare eye disease• Delivered 9 major domestic and international conference presentations to 200+ people, assisted in writing 3 NIH grants, resulted in $5M+ grant award, facilitated research collaboration between the US and China

• 3+ years clinical experience, authored 2 chapters of clinical guidelines, assisted in writing 2 clinical research grants, led to $100K+ grant award, facilitated collaboration between BTH & Chinese Univ. of Hong Kong• Led a team of 4 people, initiated the establishment of the largest pediatric ocular tumor patient database in China (500+ cases, 10+ years range), with potential for future genetic counseling and prenatal diagnosis usage

Doctor Of Philosophy (Ph.D.), Molecular Biology And Genetics

Master Of Business Administration (M.B.A.)

Master’S Degree, Ophthalmology

Doctor Of Medicine (M.D.), Clinical Medicine